ArticleMolecular biology reports2025
Antibacterial and immuno-oxidative effects of Melittin against Helicobacter pylori: in vitro and in vivo evidence.
Article in Molecular biology reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHelicobacter pylori (H. pylori) is a common pathogen that causes serious pathologies such as gastritis, ulcers, and gastric cancer. This study evaluates the therapeutic effects of melittin on H. pylori induced gastric injury, oxidative stress, and tissue damage in an in vivo model. METHODS AND
resultsMelittin was administered at two doses (10 µg/kg and 40 µg/kg) and outcomes were compared with standard antibiotic therapy. H. pylori infection significantly increased gastric urease activity, the pro-inflammatory cytokine IL-1β, and oxidative stress markers total oxidant status (TOS) and malondialdehyde (MDA); these increases were suppressed by melittin treatment. Melittin also enhanced antioxidant capacity total antioxidant status (TAS) and glutathione (GSH) and supported gastric tissue healing by reducing inflammation and neutrophil activity. Notably, 10 µg/kg melittin led to a ~ 74% reduction in bacterial colony counts and decreased tissue damage. Histopathology confirmed that melittin lowered H. pylori colonization and inflammation scores. Furthermore, the higher dose (40 µg/kg) showed more limited effects on oxidative stress than the lower dose. GSH levels improved with melittin.
conclusionsMelittin demonstrates antibacterial and anti-inflammatory activity against H. pylori associated gastric pathology, with several outcomes favoring the lower dose (10 µg/kg). These findings indicate melittin as a promising therapeutic candidate; however, additional comprehensive studies are needed to support clinical translation.
Indexed as
Identifiers
41348404What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.